DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7b93bf/epicast_report) has announced the addition of the "EpiCast Report: Duchenne Muscular Dystrophy - Epidemiology Forecast to 2023" report to their offering.
The Duchenne Muscular Dystrophy (DMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for DMD in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DMD and Becker Muscular Dystrophy (BMD) in men, segmented by age (in 10-year age groups beginning at 0 years and ending at =40 years for cases of DMD with a special focus on the subgroup of ages 5-13 years, and in 15-year age groups beginning at 0 years and ending at =75 years for cases of BMD) in these markets. Additionally, the diagnosed prevalent cases of DMD (all ages) are further segmented by the applicability of exon skipping therapies (exons 51, 45, 53, and 44) and nonsense mutations.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global DMD market.
- Quantify patient populations in the global DMD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for DMD therapeutics in each of the markets covered.
Key Topics Covered:
1 Tables & Figures
For more information visit http://www.researchandmarkets.com/research/7b93bf/epicast_report